<a href="https://www.medchemexpress.com/PF-01247324.html">PF-01247324</a>產(chǎn)品描述:PF-01247324 is a selective and orally bioavailable <b>Na<sub>v</sub>1.8</b> channel blocker with an <b>IC<sub>50</sub></b> of 196 nM for recombinant human Na<sub>v</sub>1.8 channel. IC50 & Target: IC50: 196 nM (hNa<sub>v</sub>1.8)<sup>[1]</sup> <i><b>In Vitro:</b></i> PF-01247324 inhibits native tetrodotoxin-resistant (TTX-R) currents in human dorsal root ganglion (DRG) neurons (IC<sub>50</sub>=331 nM) and in recombinantly expressed h Na<sub>v</sub>1.8 channels (IC<sub>50</sub>=196 nM), with 50-fold selectivity over recombinantly expressed TTX-R hNav1.5 channels (IC<sub>50</sub>=10 μM) and 65-100-fold selectivity over TTX-sensitive (TTX-S) channels (IC<sub>50</sub>=10-18 μM). <i>In vitro</i> current clamp shows that PF-01247324 reduces excitability in both rat and human DRG neurons and also alters the waveform of the action potential<sup>[1]</sup>. <i><b>In Vivo:</b></i> Experiments n rodents demonstrates efficacy in both inflammatory and neuropathic pain models. PF-01247324 redu<br><br> <br> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">公司介紹:MedChemExpress(MCE)專注于各種抑制劑、激動劑、API及化合物庫,總部位于美國新澤西,分別在瑞典和上海設有歐洲區(qū)子公司和亞洲區(qū)總代理,營銷網(wǎng)點遍及全球20多個國家地區(qū)。MCE經(jīng)過多年努力已成為全球生物活性小分子領域的一流供應商, 產(chǎn)品涵蓋癌癥、神經(jīng)科學、抗感染、表觀遺傳學等20個熱門研究領域,PI3K、MAPK等近千個細分靶點,超過4000個活性小分子化合物現(xiàn)貨,以及GPCR、API、離子通道等超過20種不同類型的化合物庫,同時提供從毫克到千克的專業(yè)定制合成服務。</span> <br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">MCE 對每批產(chǎn)品都進行嚴格的LCMS和NMR檢驗,其產(chǎn)品已被全球近萬名客戶廣泛使用并發(fā)表大量文章、專利;</span> <br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">MCE 定期增加各領域熱門抑制劑、激動劑,不斷擴增已有化合物庫,以滿足最新的科研需求;</span> <br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">數(shù)千種產(chǎn)品在上海有充足備貨,24-48小時內(nèi)送達客戶;</span> <br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">大量產(chǎn)品提供免費試用裝;</span> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);"> 已為全球多個知名企業(yè)、院校構建各種定制型化合物庫。</span><br><br>產(chǎn)品鏈接:<a href="http://www.medchemexpress.cn/pf-01247324.html">www.medchemexpress.cn/pf-01247324.html</a><br><br></span><img style="width: 600.0px;height: 310.0px;" src="http://img.dxycdn.com/trademd/upload/userfiles/image/2014/08/A1408605159png_small.jpg" alt=""> |
PF-01247324研究進展
發(fā)布日期:2017-10-30 瀏覽次數(shù):0
核心提示:a href=https://www.medchemexpress.com/PF-01247324.htmlPF-01247324/a產(chǎn)品描述:PF-01247324 is a selective and orally bioav
- 下一篇:暫無
- 上一篇:CFI-402257研究進展
行業(yè)動態(tài)
更多...
- PF-01247324研究進展 10-30
- CFI-402257研究進展 10-30
- Veliparib (dihydrochlori 10-30
- Paprotrain研究進展 10-30
- Z-IETD-FMK研究進展 10-30
- PD-166866研究進展 10-30
- Pan-RAS-IN-1研究進展 10-30
- CFI-402257研究進展 10-27
- Veliparib (dihydrochlori 10-27
- Paprotrain研究進展 10-27